Bristol Myers Squibb (CELG-RI) Equity Income (2009 - 2024)
Bristol Myers Squibb (CELG-RI) reported Equity Income of -$23.0 million for Q3 2024, down 227.78% year-over-year from $18.0 million in Q4 2023, and down 182.14% quarter-over-quarter from $28.0 million in Q2 2024.
Bristol Myers Squibb (CELG-RI) Equity Income (2009 - 2024) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 15 years of Equity Income data on file, last reported at -$23.0 million in Q3 2024.
- Equity Income for Q3 2024 came in at -$23.0 million, down 227.78% year-over-year; the trailing twelve-month figure through Sep 2024 was $12.0 million (down 84.42% YoY), and the FY2019 annual result was -$4.0 million, down 104.3% from the prior year.
- Equity Income retreated to -$23.0 million in Q3 2024 per CELG-RI's latest filing, from $28.0 million in the prior quarter.
- Over five years, Equity Income peaked at $40.0 million in Q3 2021 and troughed at -$23.0 million in Q3 2024.
- A 4-year average of $13.7 million and a median of $23.0 million in 2023 frame the typical range for Equity Income.
- On a YoY basis, Equity Income climbed as much as 354.55% in 2024 and fell as far as 227.78% in 2024.
- A 4-year view of Equity Income shows it stood at $30.0 million in 2020, then soared by 33.33% to $40.0 million in 2021, then plunged by 55.0% to $18.0 million in 2023, then plunged by 227.78% to -$23.0 million in 2024.
- Business Quant data shows CELG-RI's Equity Income at -$23.0 million in Q3 2024, $28.0 million in Q2 2024, and $18.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -5.39 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -23.00 Mn |
| Jun 30, 2024 | 28.00 Mn |
| Sep 30, 2023 | 18.00 Mn |
| Jun 30, 2023 | -11.00 Mn |
| Sep 30, 2021 | 40.00 Mn |
| Sep 30, 2020 | 30.00 Mn |
| Dec 31, 2019 | -4.00 Mn |
| Dec 31, 2018 | 20.00 Mn |
| Sep 30, 2018 | 22.00 Mn |
| Jun 30, 2018 | 27.00 Mn |
| Mar 31, 2018 | 24.00 Mn |
| Dec 31, 2017 | 16.00 Mn |
| Sep 30, 2017 | 21.00 Mn |
| Jun 30, 2017 | 20.00 Mn |
| Mar 31, 2017 | 18.00 Mn |
| Dec 31, 2016 | 12.00 Mn |
| Sep 30, 2016 | 19.00 Mn |
| Jun 30, 2016 | 20.00 Mn |
| Mar 31, 2016 | 26.00 Mn |
| Dec 31, 2015 | 16.00 Mn |